Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health

Lyon, France, 20 September 2019 - Boehringer Ingelheim is developing one of the largest biotechnology production sites for veterinary vaccines in Europe, building on France’s pioneering expertise in veterinary public health (VPH). The first brick was symbolically laid for this complex on Friday 20 September by French Minister of Agriculture and Food Didier Guillaume, President of the Lyon metropolitan area David Kimelfeld and Mayor of Lyon Gérard Collomb at the facility’s location in the commune of Jonage, in the eastern part of the Lyon metropolitan area.

This investment of more than 200 million euro will significantly increase production capacities for antigens and vaccines against highly contagious diseases, providing the means to fight animal epidemics that often have dramatic health and financial consequences, such as foot-and-mouth disease and bluetongue disease.

“France's highly favorable health situation is widely recognized internationally, as well as its high level of expertise in the veterinary field. However, in a context of global trade and global warming, vigilance is needed, whether it is foot-and-mouth disease, African swine fever or avian influenza. Strengthening our vaccine production capacities is therefore a major strategic challenge at national, European and global level,” said Minister of Agriculture and Food Didier Guillaume during his remarks at the event.

This high-security, 15,000 m² building will begin operating during the third quarter of 2022. Its five floors will be home to 35 cell and virus culture tanks, a purification area, a decontamination station and a strategic active ingredient reserve. This antigen bank will enable the company to quickly and efficiently respond to government orders in case of an epizootic outbreak of foot-and-mouth disease or bluetongue disease. With this new site, the company is creating more than 100 skilled jobs.

 “In the future, we will be able to supply millions of doses in a few days from Lyon for ring vaccination in affected areas to stop the progression of the disease. This is a major challenge given the impact of epidemics in the animal population,” explains Erick Lelouche, president of Boehringer Ingelheim Animal Health France.

VPH is one of Boehringer Ingelheim’s development priorities, and the company is a leader in this market segment, particularly for foot-and-mouth disease, rabies and bluetongue disease. For more than 70 years, Boehringer Ingelheim has been a trusted partner of governments, public health authorities and NGOs.

With this investment, the Lyon metropolitan area will strengthen its enviable position in the heart of the European ‘vaccine valley’. A global reference hub for life sciences, the Lyon region has become the nerve center for Boehringer Ingelheim in France. The group already employs more than 1,500 people at five sites, including Lyon Porte-des-Alpes in Saint-Priest, where vaccine formulation and packaging processes will be completed for vaccines produced in Jonage.

Key figures for the Jonage site:

• 35 tanks
• 23 km of piping
• 13,000 m³ of cement
• 400 people on the work site
• 600,000 hours of work for construction and commissioning

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health.

Boehringer Ingelheim

Improving patient health and quality of life is the goal of the Boehringer Ingelheim Group, which places research at the heart of its priorities. That’s why Boehringer Ingelheim focuses on diseases for which there is no satisfactory treatment to date, and on developing innovative therapies to extend patients’ life expectancy. In the field of animal health, Boehringer Ingelheim promotes advanced prevention. 

Family-owned since its foundation in 1885, Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Nearly 50,000 employees create value on a daily basis with innovation in our three core business areas: human health, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim generated sales of nearly €17.5 billion and spent more than €3.2 billion on research and development, representing 18.1 percent of its net sales. 

As a family-owned business, Boehringer Ingelheim factors future generations into its plans, with a focus on long-term success. It therefore aims for organic growth from its own resources, while also remaining open to partnerships and strategic alliances in the field of research. Boehringer Ingelheim naturally adopts a responsible attitude towards people and the environment. 

To learn more about Boehringer Ingelheim, visit www.boehringer-ingelheim.com or http://annualreport.boehringer-ingelheim.com to view our annual report.